Effect of Ubiquinol Supplementation on Ovulation Induction in Clomiphene Citrate Resistance

NCT04870502 | Completed Phase 2

• 1 other identifier: SGHM-MAR2019-OBGYN
• Study Type: interventional
• Target: 161
• Locations: 1 country
• Sites: 1

Brief Summary

Objective: To evaluate potential benefits of adding the active form of Coenzyme Q10 (Ubiquinol) to Clomiphene Citrate compared with Human Menopausal Gonadotropins (hMG) in Clomiphene Citrate resistant PCOS patients. Methods: 148 PCOS Patients with Clomiphene Citrate resistance were randomized into two groups (A and B). In group A, controlled ovarian stimulation was done by Clomiphene Citrate 150 mg daily (from 2nd till 6th day of cycle) together with Ubiquinol starting from 2nd day till day of hCG triggering in a dose of 100 mg orally once daily. In group B, hMG was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU. Serial transvaginal ultrasonography was done starting on cycle day 8 and continued till size of leading follicle reaches 18 mm or more then ovulation triggering was done. Thereafter, patients were advised for a timed intercourse (TI) after 36 hours. A blood sample was withdrawn seven days after hCG triggering, for measurement of serum progesterone. If the Patient presented with a missed period for one week, a serum sample was sent for β-hCG.

Conditions

Polycystic Ovarian Syndrome

Outcome Measures

Primary Outcomes (4)

• Change of the number of cases achieving follicular growth to the size of mature follicle ≥ 18 mm (1-3 follicles) during the three cycles of stimulation

  Serial transvaginal ultrasonography was done for assessment of follicular growth (number and diameter of follicles) starting on 8th day of the menstrual cycle, using vaginal 4.5 MHz endocavity transducer (Esaote Mylab 50 Xvision Ultrasound, Italy), and is continued with an interval of 1-3 days till the size of the leading follicle reaches 18 mm or more in the mean follicular diameter. The mean follicular diameter (MFD) is calculated by summation of the length and width of the growing follicle, divided by two. Mature follicle is defined as a follicle with mean diameter of 18-22 mm. The estimated period of time is 3 menstrual cycles with each menstrual cycle ranging from 3-5 weeks in duration (a total of 9-15 weeks) or till pregnancy occurs whichever came first.

  The estimated period of time is 3 menstrual cycles with each menstrual cycle ranging from 3-5 weeks in duration (a total of 9-15 weeks) or till pregnancy occurs whichever came first.

• Change of the number of stimulated cycles (till pregnancy occurs or completing the 3 cycles of the study, whichever is earlier).

  Controlled ovarian stimulation is carried out for 3 menstrual cycles. Each menstrual cycle is of 3-5 weeks duration. The estimated period of time is 3 menstrual cycles (total of 9-15 weeks) or till pregnancy occurs whichever came first.

  The estimated period of time is 3 menstrual cycles with each menstrual cycle ranging from 3-5 weeks in duration (a total of 9-15 weeks) or till pregnancy occurs whichever came first.

• Change of Luteal function as assessed by mid-luteal serum progesterone measurements.

  Patients were asked to come for follow up, 7 days after hCG triggering, where a blood sample (2 mL) was withdrawn for measurement of serum progesterone (ng/mL). Collected samples were centrifuged and then stored at 2-8 °C until enzyme immunoassay was done. Normal luteal function was defined as mid-luteal serum progesterone levels \> 10 ng/mL. This is carried out for 3 menstrual cycles of controlled ovarian stimulation. Each menstrual cycle is of 3-5 weeks duration. The estimated period of time is 3 menstrual cycles (total of 9-15 weeks) or till pregnancy occurs whichever came first.

  The estimated period of time is 3 menstrual cycles with each menstrual cycle ranging from 3-5 weeks in duration (a total of 9-15 weeks) or till pregnancy occurs whichever came first.

• Change of Endometrial thickness (mm) on the day of hCG triggering

  Transvaginal ultrasonography was done for assessment of endometrial thickness in mm (measured on sagittal view of the uterus by including the whole endometrium at the point of its maximum thickness) on the day of hCG triggering using vaginal 4.5 MHz endocavity transducer (Esaote Mylab 50 Xvision Ultrasound, Italy). This is carried out for 3 menstrual cycles of controlled ovarian stimulation. Each menstrual cycle is of 3-5 weeks duration. The estimated period of time is 3 menstrual cycles (total of 9-15 weeks) or till pregnancy occurs whichever came first.

  The estimated period of time is 3 menstrual cycles with each menstrual cycle ranging from 3-5 weeks in duration (a total of 9-15 weeks) or till pregnancy occurs whichever came first.

Secondary Outcomes (2)

• Change of the number of cases with positive serum pregnancy test (Chemical pregnancy)

  The estimated period of time is 3 menstrual cycles with each menstrual cycle ranging from 3-5 weeks in duration (a total of 9-15 weeks) or till pregnancy occurs whichever came first.

• Change of Clinical pregnancy rate

  The estimated period of time is 3 menstrual cycles with each menstrual cycle ranging from 3-5 weeks in duration (a total of 9-15 weeks) or till pregnancy occurs whichever came first.

Study Arms (2)

Clomiphene citrate and Ubiquinol

ACTIVE COMPARATOR

Controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals).

Drug: Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG

Human Menopausal Gonadotropins (hMG)

ACTIVE COMPARATOR

Controlled ovarian stimulation (COS) was done by Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response.

Drug: Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG

Interventions

Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG DRUG

In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.

Also known as: Fertab® 50 mg tablets, Zynova. SITCO Pharma., Nutraquinol®; Jamjoom Pharma Nutraceuticals, Merional® 75 I.U. vials, IBSA

Clomiphene citrate and Ubiquinol; Human Menopausal Gonadotropins (hMG)

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age 18 to 35 years
• Body mass index (BMI) between 18.5 and 34.9 kg/m2
• Presenting with primary or secondary infertility.
• PCOS was diagnosed according to the Rotterdam ESHRE/ASRM Consensus workshop, with at least 2 of the following 3 criteria:
• A- Oligo- and/or anovulation; manifested by oligomenorrhea or amenorrhea. Oligomenorrhea was defined as cycle interval of more than 35 days but less than six months. Amenorrhea was defined as absence of menstruation for six months or more.
• B- Hyperandrogenism; biochemical and/or clinical in the form of acne or hirsutism defined as a score of 8 or higher using the modified Ferriman-Gallwey scoring system when abnormal hair distribution was assessed in nine body areas and given a score of 0 to 4.
• C - Polycystic ovarian morphology detected by transvaginal ultrasound with the presence of 12 or more follicles measuring 2-9 mm in diameter in one or both ovaries, and/or increased ovarian volume \>10 mL.
• Clomiphene Citrate resistance was defined as failure of ovulation after administration of Clomiphene Citrate in a dose of 150 mg for 5 days per cycle, for two or three cycles.
• Patent both fallopian tubes and normal uterine cavity as evidenced by hysterosalpingography (HSG).
• Their partners had normal semen parameters as defined by the modified WHO 2010 criteria.

You may not qualify if:

• Morbidly obese patients with BMI ≥35 Kg/2m.
• Abnormal husband semen analysis.
• Abnormal HSG or laparoscopic evidence of pelvic adhesions.
• Patients receiving statin drugs for cholesterol, beta-blockers for high blood pressure, or tricyclic antidepressants, were also excluded as these drugs can lower the levels of ubiquinol in the body.

Sponsors & Collaborators

• Saudi German Hospital - Madinah: lead

Study Sites (1)

Saudi German Hospital

Al Madīnah, Madinah, 41311, Saudi Arabia

Location

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Interventions

Tablets

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Dosage Forms; Pharmaceutical Preparations

Study Officials

• Islam Mohamed Magdi Ammar, M.D.

  Saudi German Hospital - Madinah

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor and Consultant of Obstetrics and Gynecology

Study Record Dates

• First Submitted: April 9, 2021
• First Posted: May 3, 2021
• Study Start: April 1, 2019
• Primary Completion: July 31, 2020
• Study Completion: July 31, 2020
• Last Updated: May 3, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

SA (1)